Year in Review: Updates in Treating Myelofibrosis : Episode 4

Opinion

Video

March 13, 2024

Navtemadlin Plus Ruxolitinib for Patients With MF who had Suboptimal Responses to Ruxolitinib

Author(s):

Andrew Kuykendall, MD,Raajit K. Rampal, MD, PhD

Raajit K. Rampal, MD, PhD, discusses promising data on navtemadlin plus ruxolitinib for patients with myelofibrosis who had suboptimal responses to ruxolitinib, showing significant improvements in spleen and symptom responses, with further phase 3 studies anticipated.

EP: 1.How JAK Inhibitors Have Shaped the Landscape of MF

EP: 2.Pelabresib Plus Ruxolitinib for JAK Inhibitor-Naïve Patients: Data From MANIFEST and MANIFEST-2

EP: 3.Navitoclax Plus Ruxolitinib for Untreated MF: Data From TRANSFORM-1

EP: 4.Navtemadlin Plus Ruxolitinib for Patients With MF who had Suboptimal Responses to Ruxolitinib

EP: 5.Selinexor Plus Ruxolitinib in JAK Inhibitor-Naïve Patients: Updated Results From XPORT-MF-034

EP: 6.Luspatercept With or Without Ruxolitinib for the Treatment of Anemia in Patients With MF: Data From ACE-536-MF-001

EP: 7.Future Directions in Combination Therapies for Myelofibrosis

EP: 8.Key Efficacy and Safety Takeaways From Recent Data on JAK Inhibitors for MF

EP: 9.The FREEDOM-2 Trial: Efficacy and Safety of Fedratinib in Patients With MF Previously Treated With Ruxolitinib

EP: 10.Selection and Sequencing of JAK Inhibitors for Patients With MF

EP: 11.Individualizing Therapy Goals for Patients With Myelofibrosis

EP: 12.Emerging Treatments for Myelofibrosis

Related Videos

Sangeetha Venugopal, MD, MS, discusses factors that inform JAK inhibitor selection in myelofibrosis.

Ashkan Emadi, MD, PhD

Amer Zeidan, MBBS, and Guillermo Garcia-Manero, MD, discuss current treatment trends in myelodysplastic syndromes.

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.

$Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma$

Eunice S. Wang, MD

Nosha Farhadfar, MD, and Chandler Park, MD, FACP

Mikkael A. Sekeres, MD, discusses the results of combining luspatercept and lenalidomide in lower-risk, non–5q deletion myelodysplastic syndromes.

Prithviraj Bose, MD, and Chandler Park, MD, FACP

Related Content

Acute Myeloid Leukemia | stock.adobe.com

December 20th 2024

Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital

November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

CP-CML | Image Credit: © สุพัฒตรา แสนพลี – stock.adobe.com

December 19th 2024

Olverembatinib Demonstrates Efficacy and Safety in Heavily Pretreated CP-CML

OncLive On Air

March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

FDA

December 18th 2024

FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease

Orca-Q in Hematologic Malignancies | Image Credit: © Tatiana Shepeleva - stock.adobe.com

December 16th 2024

Orca-Q Leads to Low Rates of GVHD, Non-Relapse Mortality in High-Risk Hematologic Malignancies After Allo-HCT

Related Content

Acute Myeloid Leukemia | stock.adobe.com

December 20th 2024

Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML

Paul J. Shaughnessy, MD, medical director, Adult Blood and Marrow Stem Cell Transplant Program, Methodist Hospital

November 28th 2024

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

CP-CML | Image Credit: © สุพัฒตรา แสนพลี – stock.adobe.com

December 19th 2024

Olverembatinib Demonstrates Efficacy and Safety in Heavily Pretreated CP-CML

OncLive On Air

March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

FDA

December 18th 2024

FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease

Orca-Q in Hematologic Malignancies | Image Credit: © Tatiana Shepeleva - stock.adobe.com

December 16th 2024

Orca-Q Leads to Low Rates of GVHD, Non-Relapse Mortality in High-Risk Hematologic Malignancies After Allo-HCT

Latest Conference Coverage

Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC

Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

View More Latest Conference Coverage

Editorial Board

MJH Life Sciences brands

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.